



**Flo seal**  
Hemostatic Matrix



**Because  
one less  
transfusion  
matters.**

Compared to SURGICEL and GELFOAM  
in CV procedures, FLOSEAL has been  
shown to provide<sup>1</sup>:


- 53% lower transfusion rate
- 67% lower revision rate
- 24 minutes less operative time\*

\*between decannulation and closure of the sternum

**Baxter**

# Because Every Millilitre, Bleed and Minute Matters

## Transfusion of Blood Products<sup>1</sup>




**53% lower**

percentage of patients

*p*<0.001

## Operative Time<sup>1\*</sup>




**24 minutes**

minutes saved

*p*<0.001

## Revision for Bleeding<sup>1</sup>




**67% lower**

percentage of patients

*p*<0.04

## Minor Complications<sup>1</sup>



**38% reduction**

percentage of patients

*p*<0.04

\*Operative time comprised between decannulation and closure of sternum.

In a prospective, randomized, controlled trial for cardiovascular surgery, a cohort of patients with intraoperative bleeding was treated with FLOSEAL Matrix (n=110) or control (n=104), with either SURGICEL hemostat or GELFOAM sponge. The number of patients requiring transfusion of blood products or with minor complications (renal failure, respiratory insufficiency, or inotropic support lasting more than 24 hours), as well as the operative time and number of patients with surgical revisions for bleeding, were significantly less in the FLOSEAL Matrix group. No difference in major complications (stroke, shock, sepsis, or myocardial infarction) or ICU stay was observed between groups during the study.<sup>1</sup>

**FLOSEAL [Hemostatic Matrix] Indications:** FLOSEAL is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding, ranging from oozing to spurting, by ligature or conventional procedures is ineffective or impractical.

**Contraindications:** Do not use FLOSEAL in patients with known allergies to materials of bovine origin.

**Warnings:** Do not inject or compress FLOSEAL into blood vessels. For a complete list of all warnings please refer to your IFU.

1. Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the Floseal matrix sealant in cardiac surgery. *Ann Thorac Surg.* 2009;88:1520-1526.

For questions or ordering information, please contact your Baxter representative.

[www.floseal.com/int](http://www.floseal.com/int)

**Baxter**

Baxter Healthcare S.A.  
Postbox  
CH-8010 Zuerich

Baxter and Floseal are registered trademarks of Baxter International Inc.  
All other products or trademarks appearing herein are the property of their respective owners.  
©2016 Baxter International Inc. All rights reserved.

EUMP/9/16-0019 May 2016